Protein C News and Research

RSS

Mason scientists receive DOD funding for breast cancer prevention and treatment research

George Mason University College of Science announced a $1.57 million dollar grant from the Department of Defense to fund a transformative approach for breast cancer treatment developed by scientists in Mason's Center for Drug Discovery for Rare Diseases.

15 Mar 2022

Cognitive decline found to be the key factor in predicting life expectancy for Alzheimer's patients

Cognitive decline is the biggest factor in determining how long patients with Alzheimer's disease will live after being diagnosed, according to a new study from researchers at UT Southwestern.

15 Mar 2022

Do anti-nucleocapsid antibodies affect COVID-19 immune reactions?

Researchers have been investigating the potential for vaccines and treatments against the nucleocapsid protein of SARS-CoV-2.

15 Mar 2022

Study finds elevated inflammation in macrophages months after mild COVID-19

There is a lack of understanding as to why some people suffer from long-lasting symptoms after COVID-19 infection.

15 Mar 2022

Moderate hyperglycemia associated with poor COVID-19 prognosis

Scientists have revealed that non-diabetic patients with moderate hyperglycemia are more likely to develop severe and fatal COVID-19 than diabetic patients.

15 Mar 2022

Sustainable material-based biosensors for SARS-CoV-2 detection

Researchers conducted a brief review on biosensors based on sustainable materials for SARS-CoV-2 detection.

15 Mar 2022

Study models SARS-CoV-2 M protein monomer and dimer 3D structures

Researchers presented new structural insights about the SARS-CoV-2 membrane protein.

15 Mar 2022

Identification of linear B cell epitopes in the SARS-CoV-2 proteome that are conserved in humans coronaviruses

Researchers identified and validated multiple linear B-cell epitopes in the SARS-CoV-2 proteomes conserved in humans coronaviruses.

15 Mar 2022

Antimicrobial prescribing among infants may be prevented using maternal RSV vaccines

RSV is a leading cause of severe acute lower respiratory tract infections (LRTIs) among infants globally, and a prominent contributor to common non-severe infections that account for high volumes of antibiotic consumption.

14 Mar 2022

Using mRNA to introduce gene editor into human muscle stem cells

Mutations that lead to muscle atrophy can be repaired with the gene editor CRISPR-Cas9. A team led by ECRC researcher Helena Escobar has now introduced the tool into human muscle stem cells for the first time using mRNA, thus discovering a method suitable for therapeutic applications.

14 Mar 2022

Researchers find unusual way of stabilizing cancer-suppressing protein

The p53 protein protects our cells from cancer and is an interesting target for cancer treatments. The problem is, however, that it breaks down rapidly in the cell. Researchers at Karolinska Institutet in Sweden have now found an unusual way of stabilizing the protein and making it more potent.

14 Mar 2022

New Phase 1 clinical trial of mRNA HIV vaccine enrolls first participant

The first 12 study participants have been enrolled in a new Phase 1 clinical trial using the messenger ribonucleic acid (mRNA) vaccine technology developed by Moderna.

14 Mar 2022

Malaria drug could help treat chemotherapy-resistant head and neck cancers

A new study suggests that the malaria drug hydroxychloroquine inhibits pathways that drive resistance to the chemotherapy agent cisplatin in head and neck cancers and restores tumor-killing effects of cisplatin in animal models.

14 Mar 2022

First genetic rat model of Down syndrome offers better understanding of the condition

In pursuit of better ways to test new therapies and further explore the impacts of the unique genetics associated with Down syndrome, researchers at Johns Hopkins Medicine and Tottori University in Japan have genetically engineered and characterized what is believed to be the first rat model of Down syndrome.

14 Mar 2022

NIH launches Phase 1 clinical trial evaluating three experimental mRNA HIV vaccines

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched a Phase 1 clinical trial evaluating three experimental HIV vaccines based on a messenger RNA (mRNA) platform—a technology used in several approved COVID-19 vaccines.

14 Mar 2022